Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Jul;10(1):e001698.
doi: 10.1136/bmjresp-2023-001698.

Burden of COPD in China and the global from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019

Min Li  1 , Chen Hanxiang  1 , Zhou Na  2 , Zhang Ping  3 , Duan Shengnan  1 , Wu Taihua  4 , Yi Yuanyuan  5 , Yuan Ni  6   7
Affiliations
Observational Study

Burden of COPD in China and the global from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019

Min Li et al. BMJ Open Respir Res. 2023 Jul.

Abstract

Objective: To investigate the current disease burden of chronic obstructive pulmonary disease (COPD) in China and globally using the Global Burden of Disease (GBD) data in 2019, as well as to analyse the changes in its risk factors, providing a scientific basis for the formulation of a comprehensive prevention and control strategy for COPD in China.

Study design: An observational study based on the GBDs.

Methods: Based on the GBD 2019 database, we obtained data on incidence, prevalence, mortality, disability-adjusted life years (DALYs) and corresponding age-standardised rates of COPD in China and the global, and analysed and described the changing trends of COPD burden in China and the global from 1990 to 2019.

Results: In 2019, the total number of COPD deaths in China was 1.04 (95% uncertainty intervals (95% UI): 0.89-1.27) million cases, the number of patients with COPD was 45.16 (95% UI: 41.13-49.62) million cases, and the number of new cases was 4.0 (95% UI: 3.6-4.4) million cases. DALYs were 74.4 (95% UI: 68.2-80.2) million years. Compared with 1990, the number of new incident cases and the overall prevalence of COPD in China in 2019 increased by 66.20% and 66.76%, respectively, which is lower than the overall global level.

Conclusion: From 1990 to 2019, the age-standardized prevalence rate (ASPR), the age-standardized incidence rate (ASIR) and the age-standardized death rate (ASDR) in China and the global all showed a downward trend, and the rate of decline in China was much higher than the overall level of the world, indicating that China has made specific achievements in the prevention and treatment of COPD, but overall the disease burden of COPD is still hefty, and the number of affected individuals is still increasing.

Keywords: COPD Pathology; COPD Pharmacology; COPD epidemiology; COPD ÀÜ Mechanisms; Health Economist.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Death cases and death rate of chronic obstructive pulmonary disease by age group in China and globally, 1990–2019.
Figure 2
Figure 2
Incident cases and incidence rate of chronic obstructive pulmonary disease by age group in China and globally, 1990–2019.
Figure 3
Figure 3
Prevalent cases and prevalence rate of chronic obstructive pulmonary disease by age group in China and globally, 1990–2019.
Figure 4
Figure 4
New cases and ASIR (age-standardized incidence rate) of chronic obstructive pulmonary disease in China and global, 1990–2019.
Figure 5
Figure 5
Total cases of chronic obstructive pulmonary disease in China and global, 1990–2019 and ASPR (age-standardized prevalence rate).
Figure 6
Figure 6
Total number of chronic obstructive pulmonary disease deaths and ASDR (age-standardized death rate) in China and globally, 1990–2019.
Figure 7
Figure 7
Trends of ASR–DALYs in China and global chronic obstructive pulmonary disease from 1990 to 2019. ASR, age-standardised rate; DALY, disability-adjusted life year.
Figure 8
Figure 8
Trends of ASR–YLD in China and global chronic obstructive pulmonary disease from 1990 to 2019. ASR, age-standardised rate; YLD, years lived with disability.
Figure 9
Figure 9
Trends of ASR–YLL in China and global chronic obstructive pulmonary disease from 1990 to 2019. ASR, age-standardised rate; YLL, years of life lost.
Figure 10
Figure 10
Changes of risk factors for chronic obstructive pulmonary disease in China from 1990 to 2019. ASR, age-standardised rate.
Figure 11
Figure 11
Changes of risk factors for chronic obstructive pulmonary disease in global from 1990 to 2019. ASR, age-standardised rate.
See this image and copyright information in PMC

References

    1. Initiative for Chronic Obstructive Lung Disease (GOLD) . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2022 report).
    1. GBD Chronic Respiratory Disease Collaborators . Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med 2020;8:585–96. 10.1016/S2213-2600(20)30105-3 - DOI - PMC - PubMed
    1. Adeloye D, Chua S, Lee C, et al. . Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health 2015;5. 10.7189/jogh.05.020415 - DOI - PMC - PubMed
    1. World Health Organization . WHO package of essential Noncommunicable (PEN) disease interventions for primary health care. World Health Organization; 2022. Available: https://www.who.int/publications/i/item/who-package-of-essential-noncomm...
    1. World Health Organization . The top 10 causes of death. World Health Organization; 2022. Available: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death

Publication types